Slide background

Welcome to La Jolla Pharmaceutical Company, where we're dedicated to developing treatments that significantly improve outcomes in patients with life threatening diseases.

Learn More

Slide background

Our current efforts focus on the clinical evaluation of treatments for chronic organ disease and hepatorenal syndrome, a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure....

Learn More

Slide background

Our researchers are focused on expanding our pipeline by developing innovative new therapies...

Learn More

Our Leading Drug Candidates: GCS-100, LJPC-401, and LJPC-501

Our drug development efforts are focused on three product candidates, GCS-100, LJPC-401, and LJPC-501. Our lead product, GCS-100, focuses on modulation of galectin-3, a member of the galectin family of proteins, while our second product candidate, LJPC-501, is a peptide agonist of the renin-angiotensin system that acts to help the kidneys balance body fluids and electrolytes. Our third product candidate, LJPC-401, is a formulation of Hepcidin, a endogenous peptide hormone that regulates dietary iron absorption and tissue distribution.